PMID- 31213774
OWN - NLM
STAT- MEDLINE
DCOM- 20191223
LR  - 20200225
IS  - 1177-8881 (Electronic)
IS  - 1177-8881 (Linking)
VI  - 13
DP  - 2019
TI  - Efficacy and toxicity of cladribine for the treatment of refractory acute myeloid 
      leukemia: a meta-analysis.
PG  - 1867-1878
LID - 10.2147/DDDT.S207425 [doi]
AB  - Purpose: To investigate the overall efficacy and toxicity of cladribine and 
      cladribine-based chemotherapy in the treatment of patients with refractory acute 
      myeloid leukemia (AML) based on meta-analysis. Methods: PubMed, EMBASE database, 
      and the Cochrane Library were searched for relevant studies. Eligible studies 
      were clinical trials of refractory AML assigned to cladribine with data on 
      efficacy including complete remission (CR) rate, overall response rate (ORR) and 
      overall survival. Toxicity was evaluated based on the early death rate and the 
      incidence of grade 3 and 4 adverse events (AEs). Results: A total of 10 clinical 
      trials including 422 refractory AML patients were analyzed. The overall CR rate 
      was 42.2% (95% CI: 31.0-54.3%). And the ORR of seven trials including 235 
      patients was 49.7% (95% CI: 33.5-66.0%). The overall early death rate of 260 
      patients enrolled in five trials was 6.8% (95% CI: 4.3-10.6%). Thrombocytopenia, 
      anemia, neutropenia, and infection were the most common grade 3 and 4 AEs. 
      Conclusion: Cladribine is effective for refractory AML, and its efficacy can be 
      increased with the combination of cladribine, cytarabine, and granulocyte-colony 
      stimulating factor regimen.
FAU - Zhou, Anqi
AU  - Zhou A
AD  - Department of Hematology, Zhongda Hospital Southeast University, Institute of 
      Hematology Southeast University, Nanjing 210009, People's Republic of China.
FAU - Han, Qi
AU  - Han Q
AD  - Department of Hematology, Zhongda Hospital Southeast University, Institute of 
      Hematology Southeast University, Nanjing 210009, People's Republic of China.
FAU - Song, Huihui
AU  - Song H
AD  - Department of Hematology, Zhongda Hospital Southeast University, Institute of 
      Hematology Southeast University, Nanjing 210009, People's Republic of China.
FAU - Zi, Jie
AU  - Zi J
AD  - Department of Hematology, Zhongda Hospital Southeast University, Institute of 
      Hematology Southeast University, Nanjing 210009, People's Republic of China.
FAU - Ma, Jinlong
AU  - Ma J
AD  - Department of Hematology, Zhongda Hospital Southeast University, Institute of 
      Hematology Southeast University, Nanjing 210009, People's Republic of China.
FAU - Ge, Zheng
AU  - Ge Z
AD  - Department of Hematology, Zhongda Hospital Southeast University, Institute of 
      Hematology Southeast University, Nanjing 210009, People's Republic of China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
DEP - 20190529
PL  - New Zealand
TA  - Drug Des Devel Ther
JT  - Drug design, development and therapy
JID - 101475745
RN  - 47M74X9YT5 (Cladribine)
SB  - IM
MH  - Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use
MH  - Cladribine/adverse effects/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Humans
MH  - Leukemia, Myeloid, Acute/*drug therapy/pathology
PMC - PMC6549775
OTO - NOTNLM
OT  - acute myeloid leukemia
OT  - cladribine
OT  - meta-analysis
OT  - refractory AML
COIS- The authors report no conflicts of interest in this work.
EDAT- 2019/06/20 06:00
MHDA- 2019/12/24 06:00
PMCR- 2019/05/29
CRDT- 2019/06/20 06:00
PHST- 2019/03/03 00:00 [received]
PHST- 2019/04/26 00:00 [accepted]
PHST- 2019/06/20 06:00 [entrez]
PHST- 2019/06/20 06:00 [pubmed]
PHST- 2019/12/24 06:00 [medline]
PHST- 2019/05/29 00:00 [pmc-release]
AID - 207425 [pii]
AID - 10.2147/DDDT.S207425 [doi]
PST - epublish
SO  - Drug Des Devel Ther. 2019 May 29;13:1867-1878. doi: 10.2147/DDDT.S207425. 
      eCollection 2019.